Drugs / CNTX-6016
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04857957 | Apr 2021 → Aug 2023 | diabetic polyneuropathy | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04154501 | Dec 2018 → Aug 2019 | chronic pain syndrome | Centrexion Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTX-6016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857957 ↗ |
| Route | Oral | “Oral Dose CNTX-6016” NCT04154501 ↗ |